About Naslund Medical
Naslund Medical AB is the Swedish medical device company behind Gold Anchor™—an innovative implantable soft-tissue marker designed to improve the management and care of cancer patients. Gold Anchor facilitates faster, more precise radiation therapy, enhances patient safety, and provides accurate image guidance during surgical procedures.
Headquartered in Sweden, Naslund Medical has subsidiaries in the United States, the United Kingdom, and France, supported by a global network of distribution partners.
Today, Naslund Medical and Gold Anchor are part of IZI Medical, a leading developer and manufacturer of medical devices used in interventional radiology and oncology, radiation therapy, neuro-spine, and image-guided surgery.
The addition of Gold Anchor strengthens IZI Medicalʼs position in a clinically important and growing area of cancer treatment. Together with the Visicoil™ platform, Gold Anchor expands IZI Medicalʼs portfolio and establishes the company as a leading global provider of premium fiducial markers.
Naslund Medical AB is certified to SS-EN ISO 13485:2016.
From traditional seed markers to advanced MR-compatible solutions, IZI Medical now offers a broader fiducial portfolio, providing clinicians with more options to match their preferred workflows and treatment needs.
Image from Varian Medical Systems Centerline Magazine, October 2004.
The inventor of Gold Anchor Dr. Ingemar Naslund (to the left) with physicists Bruno Sorcini and Aris Tilikidis from The Karolinska University Hospital in Stockholm, Sweden. They are standing in front of a Varian linear accelerator with onboard kV-imaging. Karolinska was one of the first in the world to install such a linear accelerator back in 2004.
A legacy of innovation
Gold Anchor was invented and developed by Ingemar Naslund, MD, PhD, an associate professor who served for 20 years as head of the Division of Radiation Therapy at Radiumhemmet, Karolinska University Hospital, in Stockholm, Sweden.
Dr. Naslund also contributed to the development of stereotactic body radiation therapy (SBRT), together with physicist Associate Professor Ingmar Lax and oncologist Associate Professor Henric Blomgren. Their early publication on the SBRT technique helped introduce an approach that has since spread worldwide and become a standard of care for certain tumors.
Building on knowledge in fine-needle aspiration cytology—pioneered at Karolinska by Dr. Sixten Franzén—and advances in onboard kV imaging, Dr. Naslund conceived a fiducial marker that could be delivered through an exceptionally thin needle.
This led to the development of Gold Anchor: a fiducial marker that can be supplied in an ultrathin 25-gauge needle, enabling image guidance in organs throughout the body. Gold Anchor has since evolved to offer a range of marker and needle sizes. Its material composition has also been enhanced with a small amount of iron to improve visibility on MRI.
As part of IZI Medical, Gold Anchor continues this legacy of clinically driven innovation, helping healthcare professionals deliver precise, efficient, and patient-focused care.
One of the fastest-growing companies in Sweden
We are happy to announce that we have been recognized for the fourth time as one of the fastest-growing companies in Sweden, receiving the prestigious Gasell award!
We couldn’t have achieved this without the incredible support of all Gold Anchor users and distributors. Together, we are making remarkable progress in advancing radiotherapy treatments. Thank you for being part of this journey!
Naslund Medical has been awarded 2019 yearʼs Swecare Export Award for its innovation power, strategy and strong exports. We are grateful, proud and happy to be part of improving cancer care throughout the world.